| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leslie Citrom. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Advances in therapy. vol 30. issue 2. 2013-12-17. PMID:23361833. |
cariprazine differs from aripiprazole in terms of dopamine d3 receptor selectivity. |
2013-12-17 |
2023-08-12 |
Not clear |
| F Jantschak, J Brosda, R T Franke, H Fink, D Möller, H Hübner, P Gmeiner, H H Pert. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats. The Journal of pharmacology and experimental therapeutics. vol 347. issue 1. 2013-11-25. PMID:23863695. |
dopamine d2 receptor partial agonists such as aripiprazole represent a treatment option for patients with this severe disorder. |
2013-11-25 |
2023-08-12 |
human |
| Tiago Moreira, Lotfi Khemiri, Lennart Runeso. Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. BMJ case reports. vol 2011. 2013-11-05. PMID:22674947. |
lithium was initially reinstated (same dose), but it was aripiprazole reinstatement at a lower dose (10 mg) that made his condition rapidly improve within 24-36 h. aripiprazole is a partial dopamine d2-receptor antagonist that blocks dopamine at higher dopamine concentrations and augments/releases prefrontal cortex dopamine at lower concentrations. |
2013-11-05 |
2023-08-12 |
Not clear |
| Tiago Moreira, Lotfi Khemiri, Lennart Runeso. Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. BMJ case reports. vol 2011. 2013-11-05. PMID:22674947. |
the rapid recovery suggests stabilisation of dopamine levels in the frontal lobes and that icd may be modified by aripiprazole treatment. |
2013-11-05 |
2023-08-12 |
Not clear |
| Thercia G Viana, Ana F Almeida-Santos, Daniele C Aguiar, Fabricio A Moreir. Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice. Basic & clinical pharmacology & toxicology. vol 112. issue 5. 2013-10-24. PMID:23157340. |
aripiprazole is an antipsychotic that acts as a partial agonist at dopamine receptors. |
2013-10-24 |
2023-08-12 |
mouse |
| Farouq I Thabet, Rochelle T Sweis, Suja A Josep. Aripiprazole-induced seizure in a 3-year-old child: a case report and literature review. Clinical neuropharmacology. vol 36. issue 1. 2013-10-17. PMID:23334073. |
aripiprazole is an atypical antipsychotic medication that is a partial dopamine d(2) and serotonin 5-hydroxytryptamine (1a) receptor agonist and 5-hydroxytryptamine (2a) receptor antagonist. |
2013-10-17 |
2023-08-12 |
Not clear |
| Shigenori Tadokor. [Aripiprazole as "dopamine sensitivity stabilizer"]. Nihon rinsho. Japanese journal of clinical medicine. vol 71. issue 4. 2013-09-25. PMID:23678600. |
[aripiprazole as "dopamine sensitivity stabilizer"]. |
2013-09-25 |
2023-08-12 |
Not clear |
| Johan Lataster, Inez Myin-Germeys, Marieke Wichers, Philippe A E G Delespaul, J van Os, Maarten Ba. Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports. Therapeutic advances in psychopharmacology. vol 1. issue 5. 2013-08-28. PMID:23983939. |
the partial d2 agonistic profile of aripiprazole has, therefore, been suggested to favor emotional wellbeing compared with the pure dopamine antagonistic properties of traditional antipsychotics. |
2013-08-28 |
2023-08-12 |
Not clear |
| Paweł Zajdel, Krzysztof Marciniec, Andrzej Maślankiewicz, Katarzyna Grychowska, Grzegorz Satała, Beata Duszyńska, Tomasz Lenda, Agata Siwek, Gabriel Nowak, Anna Partyka, Dagmara Wróbel, Magdalena Jastrzębska-Więsek, Andrzej J Bojarski, Anna Wesołowska, Maciej Pawłowsk. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. European journal of medicinal chemistry. vol 60. 2013-08-13. PMID:23279866. |
antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-ht₁a/5-ht₂a/5-ht₇ and dopamine d₂/d₃ receptors. |
2013-08-13 |
2023-08-12 |
mouse |
| Peter Paul De Deyn, Annemieke F J Drenth, Berry P Kremer, Richard C Oude Voshaar, Debby Van Da. Aripiprazole in the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy. vol 14. issue 4. 2013-08-12. PMID:23350964. |
aripiprazole is a newer atypical antipsychotic drug with partial agonist activity at dopamine receptors and antagonist activity at 5-ht(2a) receptors, with a low side-effect profile. |
2013-08-12 |
2023-08-12 |
Not clear |
| Eunjin Cheon, Bon-Hoon Koo, Sang Soo Seo, Jun-Yeob Le. Two cases of hypersexuality probably associated with aripiprazole. Psychiatry investigation. vol 10. issue 2. 2013-06-27. PMID:23798970. |
we discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological profile, partial agonism with high affinity at dopamine d2-receptor, may have contributed to the development of these symptoms. |
2013-06-27 |
2023-08-12 |
Not clear |
| Yeon Won Park, Yooseok Kim, Jun Ho Le. Antipsychotic-induced sexual dysfunction and its management. The world journal of men's health. vol 30. issue 3. 2013-04-19. PMID:23596605. |
based on the blockade of dopamine d2 receptors, haloperidol, risperidone, and amisulpride are classed as prolactin-elevating antipsychotics, while olanzapine, clozapine, quetiapine, ziprasidone, and aripiprazole are classed as prolactin-sparing drugs. |
2013-04-19 |
2023-08-12 |
Not clear |
| Kevin N Boyd, Richard B Mailma. Dopamine receptor signaling and current and future antipsychotic drugs. Handbook of experimental pharmacology. issue 212. 2013-04-17. PMID:23129328. |
we review the signaling mechanisms of currently approved apds at dopamine d(2) receptors, and note that aripiprazole is a compound that is clearly differentiated from other approved drugs. |
2013-04-17 |
2023-08-12 |
Not clear |
| Kevin N Boyd, Richard B Mailma. Dopamine receptor signaling and current and future antipsychotic drugs. Handbook of experimental pharmacology. issue 212. 2013-04-17. PMID:23129328. |
although aripiprazole has been postulated to cause dopamine stabilization due to its partial d(2) agonist properties, a body of literature suggests that an alternative mechanism, functional selectivity, is of primary importance. |
2013-04-17 |
2023-08-12 |
Not clear |
| Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Takeshi Suzuki, Kenji Nemoto, Shoko Kagawa, Ikuya Ohta, Hajime Arakaki, Tsuyoshi Kond. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and clinical neurosciences. vol 66. issue 6. 2013-04-02. PMID:23066770. |
prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine d2 receptor and cytochrome p450 2d6 in japanese patients with schizophrenia. |
2013-04-02 |
2023-08-12 |
Not clear |
| Goyo Nagai, Kazuo Mihara, Akifumi Nakamura, Takeshi Suzuki, Kenji Nemoto, Shoko Kagawa, Ikuya Ohta, Hajime Arakaki, Tsuyoshi Kond. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and clinical neurosciences. vol 66. issue 6. 2013-04-02. PMID:23066770. |
the authors investigated the correlation between prolactin concentrations during aripiprazole treatment and various factors, including age, sex, plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, and genetic polymorphisms of dopamine d2 receptor (drd2) and cytochrome p450(cyp)2d6. |
2013-04-02 |
2023-08-12 |
Not clear |
| Jennifer L Yap, Lee E Wachtel, Edward S Ahn, Jacqueline H Sanz, Beth S Slomine, Frank S Pidcoc. Treatment of cerebellar cognitive affective syndrome with aripiprazole. Journal of pediatric rehabilitation medicine. vol 5. issue 3. 2013-03-08. PMID:23023255. |
five weeks following surgery, treatment with aripiprazole, a partial dopamine agonist, was started to address the delirious state. |
2013-03-08 |
2023-08-12 |
Not clear |
| Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hidehiko Takahashi, Fumitoshi Kodaka, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Tetsuya Suhar. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PloS one. vol 7. issue 9. 2013-02-20. PMID:23029533. |
effects of dopamine d2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by pet with l-[β-11c]dopa. |
2013-02-20 |
2023-08-12 |
human |
| Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hidehiko Takahashi, Fumitoshi Kodaka, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Tetsuya Suhar. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PloS one. vol 7. issue 9. 2013-02-20. PMID:23029533. |
positron emission tomography (pet) was used to examine the effects of the partial agonist antipsychotic drug aripiprazole on presynaptic dopamine synthesis in relation to dopamine d(2) receptor occupancy and the resulting changes in dopamine synthesis capacity in healthy men. |
2013-02-20 |
2023-08-12 |
human |
| Hiroshi Ito, Harumasa Takano, Ryosuke Arakawa, Hidehiko Takahashi, Fumitoshi Kodaka, Keisuke Takahata, Tsuyoshi Nogami, Masayuki Suzuki, Tetsuya Suhar. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PloS one. vol 7. issue 9. 2013-02-20. PMID:23029533. |
occupancy of dopamine d(2) receptors corresponded to the doses of aripiprazole, but the changes in dopamine synthesis capacity were not significant, nor was the relation between dopamine d(2) receptor occupancy and these changes. |
2013-02-20 |
2023-08-12 |
human |